27 results on '"Trzaskoma, Benjamin L"'
Search Results
2. Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma
3. Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life
4. The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria
5. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
6. Proceedings of the 2017 WAO Symposium on Hot Topics in Allergy: Pediatric & Regulatory Aspects: Rome, Italy/Vatican City. 27-29 April 2017
7. The effect of omalizumab on lung function in adolescents with moderate to severe allergic asthma
8. Reduction of Exacerbations by Baseline Indicators of Asthma Severity in Children Receiving Omalizumab
9. Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study
10. Greater Treatment Benefit with Omalizumab in Children with Increased Asthma Severity: Exploratory Analyses from the Inner-City Anti-IgE Therapy for Asthma (ICATA) Study
11. The Composite Asthma Severity Index: A Tool for Assessing Impact of Omalizumab Treatment in Children with Moderate-to-Severe Persistent Allergic Asthma
12. Response to Omalizumab Observed Over Wide Range of Blood Eosinophil Levels
13. Subgroup Analysis Identifies Differences Between Sexes In How CIU Patients Respond To Omalizumab
14. The Urticaria Control Test as a Tool for Monitoring Chronic Idiopathic/Spontaneous Urticaria Treatment: Results From XTEND-CIU, a 48-Week, Randomized, Placebo-controlled Study
15. Impact of Baseline IgE levels on Exacerbations and Asthma Symptom Control After Omalizumab Initiation
16. Impact Of Omalizumab On Patient Reported Outcomes In Chronic Idiopathic Urticaria: Results From XTEND-CIU, A 48-Week, Randomized, Placebo-Controlled Study
17. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO
18. Decreased Asthma Exacerbations and Hospitalizations in PROSPERO (Prospective Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab)
19. Baseline Blood Eosinophils and Reduction of Asthma Exacerbations By Omalizumab in Children with Moderate-to-Severe Allergic Asthma
20. Study Design, Baseline and Open-Label Results from XTEND-CIU: A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab through 48 Weeks in Patients with Chronic Idiopathic Urticaria
21. Clinically Significant Improvements in Asthma Patient-Reported Outcomes: Results from the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) Study
22. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO
23. Proceedings of the 2017 WAO Symposium on Hot Topics in Allergy: Pediatric & Regulatory Aspects
24. ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation*
25. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
26. International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH
27. Failure to Improve during First Day of Therapy Is Predictive of 28-Day Mortality in Severe Sepsi
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.